Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

HER-Seq: A Blood-based Screening Study to Identify Patients With HER2 Mutations for Enrollment Into Clinical Research Studies of Neratinib

NCT03786107 is registered in ClinicalTrials.gov with Puma Biotechnology, Inc. as lead sponsor.

NCT NCT03786107
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03786107 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
HER-Seq: A Blood-based Screening Study to Identify Patients With HER2 Mutations for Enrollment Into Clinical Research Studies of Neratinib
Lead sponsor
Puma Biotechnology, Inc.
Phase
Observational
Overall status
Terminated
Start date
March 14, 2019
Completion date
January 21, 2021
Enrollment
1,583 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

hormone receptor-positive, her2-negative metastatic breast cancer, metastatic cervical cancer